

## **StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms**

**Osaka, Japan, January 15, 2025** – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; "StemRIM" or "Company") announces that the tripartite joint research agreement, initially updated on January 24, 2023, and subsequently on November 13, 2023, between our company, Shiseido Company, Limited (TSE:4911, Representative Corporate Executive Officer, President and CEO: Kentaro Fujiwara; "Shiseido"), and the Graduate School of Medicine, Osaka University ("Osaka University"), has been extended once again.

The joint research promoted by StemRIM, Shiseido, and Osaka University aims to scientifically elucidate the complex mechanisms related to the aging of skin stem cells. Based on the findings obtained, the research seeks to develop innovative pharmaceuticals and cosmetics that contribute to skin anti-aging. While significant progress has been made in understanding the physiological changes associated with stem cell aging, it was determined that further in-depth analysis and accumulation of insights are required. Consequently, the decision was made to extend the research period to pursue additional analyses and explore potential applications. Please note that details of this joint research agreement remain confidential in accordance with the contractual terms with Shiseido and Osaka University.

At this time, the extension is not expected to impact on the financial results for the fiscal year ending July 31 2025. However, we believe it will contribute to the improvement of our performance over the medium to long term.

### **About StemRIM Inc.**

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration.

Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

**Inquiries:**

StemRIM Inc.

Management & Administrator Dept.

E-Mail: [stemrim-ir@stemrim.com](mailto:stemrim-ir@stemrim.com)

Twitter: [@StemRIM\\_Inc](https://twitter.com/StemRIM_Inc)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)